Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the appointment of Jean-Paul Kress, M.D., to the Company’s Board of Directors.

Jean-Paul Kress, M.D., is the recently appointed Head of North America, Sanofi Genzyme Specialty Care Business Unit (Multiple Sclerosis, Oncology & Immunology). Prior to this appointment, Jean-Paul served as the President and CEO of Sanofi Pasteur MSD, the leading European vaccine company.

“We are very pleased to welcome Jean-Paul to our Board of Directors and gain the benefit of his commercial and organizational expertise as eteplirsen, our lead candidate for the treatment of patients with Duchenne muscular dystrophy, is pending review by the FDA,” saidEdward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. “Jean-Paul is highly respected and his global experience and insights will be invaluable as we prepare for the potential commercialization of eteplirsen.”

During his tenure with Sanofi Pasteur MSD, a joint venture between Sanofi Pasteur and Merck & Co (known as MSD outside the US and Canada), Jean-Paul embarked on a series of changes to reshape the organization to better meet the challenges of the rapidly changing vaccine industry and to drive the launches of a number of innovative new products. His ability to mobilize the organization to focus on the most critical priorities resulted in a turnaround of the business and provided a firm foundation for sustainable growth. A strong advocate for the socio-economic value of vaccination, Jean-Paul was actively involved in the development of health policy across the EU with a focus on disease prevention.

Prior to his work at Sanofi Pasteur MSD, Jean-Paul was Vice President and General Manager inFrance for Gilead, a major US-based biopharmaceutical company specialized in therapeutics for life-threatening diseases such as HIV. He joined Gilead in California in 2006 as Vice President, US Sales and Marketing.

Jean-Paul Kress holds a MD Degree from Faculté Necker-Enfants Malades in Paris, France, and is an alumnus of the prestigious Ecole Normale Supérieure in Paris, France. He sits on the Board of Directors of CNE (the ENS Alumni association). (Original Source)

Shares of Sarepta Therapeutics closed today at $32.11, up $0.21 or 0.66%. SRPT has a 1-year high of $41.47 and a 1-year low of $11.33. The stock’s 50-day moving average is $35.69 and its 200-day moving average is $26.01.

On the ratings front, Sarepta has been the subject of a number of recent research reports. In a report released today, William Blair analyst Tim Lugo maintained a Buy rating on SRPT, with a price target of $52, which represents a potential upside of 61.9% from where the stock is currently trading. Separately, on September 28, Oppenheimer’s Christopher Marai reiterated a Buy rating on the stock and has a price target of $45.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Tim Lugo and Christopher Marai have a total average return of -15.6% and 12.1% respectively. Lugo has a success rate of 26.7% and is ranked #3643 out of 3754 analysts, while Marai has a success rate of 45.5% and is ranked #228.

Overall, one research analyst has assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $46.00 which is 43.3% above where the stock opened today.

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.